Issue 10 - Mar 6, 2020
  • Coronavirus vs. oncology: Meeting cancellations, travel restrictions, fears about drug supply chain

     Forecasts of the inevitable spread of coronavirus can be difficult to ignore, especially at a time when many of us are making travel plans for this spring’s big cancer meetings.

  • Moffitt execs were made aware of Howard McLeod’s China activities, ousted researcher’s attorney says

    Howard McLeod, one of the six researchers ousted at Moffitt Cancer Center under allegations of undisclosed conflicts of interest stemming from their work in China, is publicly disputing his former employer’s characterization of his involvement with academic institutions there.

  • An Appreciation

    Clara Bloomfield, blood cancer expert and destroyer of glass ceilings, dies at 77

    By Electra D. Paskett, Ph.D.

    In 1989, I joined Cancer and Leukemia Group B and was introduced into the clinical trials world and a mighty force for good, Dr. Clara D. Bloomfield.

  • In Brief

    • Roswell Park signs on to participate in ASCO’s CancerLinQ
    • IASLC names research award after Fred R. Hirsch
    • Dunmire, Godfrey, Nissenbaum named to LLS leadership team
    • Research!America: Republicans, Democrats should prioritize research investment
    • John Sampson named president of the Duke Health physician practice
    • 49 cancer care facilities receive outstanding achievement award from American College of Surgeons Commission on Cancer
    • Fox Chase Cancer Center announces name, recertification for Palliative Care Program
  • TCCL Logo

  • Clinical Roundup

    • Cancer survival rates improve for young adults
    • Colorectal cancer burden shifts to younger adults
    • Phase III BOSTON study meets primary endpoint with significant increase in PFS
    • Keytruda meets PFS primary endpoint in phase III KEYNOTE-204
    • From scorpion to immunotherapy: City of Hope scientists repurpose toxin for first-of-its kind CAR-T cell therapy for brain tumors
    • VBI Vaccines phase I/II study demonstrates OS benefit for VBI-1901 vaccine responders in recurrent GBM
  • Drugs & Targets

    • FDA approves Sarclisa in patients with previously treated MM
    • FDA grants RMAT designation for CD30 CAR-T cell therapy in Hodgkin lymphoma indication
    • FDA grants tipifarnib Fast Track designation in T-cell lymphomas
    • Thermo Fisher Scientific to acquire QiagenN.V.
  • NCI Trials

    NCI Trials for March 2020

    The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. 

Issue 9 - Feb 28, 2020
  • ODAC: Thumbs up for Eli Lilly’s Cyramza, thumbs down for STEBA’s Tookad

    The FDA Oncologic Drugs Advisory Committee Feb. 26 voted down a vascular-targeted photodynamic therapy for early-stage, low-risk prostate cancer and, in a narrow vote, recommended approval for a combination of a VEGF receptor 2 antagonist and an EGFR-targeting tyrosine kinase inhibitor for front-line treatment of EGFR-positive non-small cell lung cancer.

  • FDA approved 11 new agents, 30 supplemental indications in cancer in 2019

    Last year, FDA approved 11 new drugs and biologics as well as 30 supplemental indications and four biosimilars, according to commentary by FDA officials published in Nature Reviews.

  • In Brief

    • Jennifer Cullen named associate director of Cancer Population Sciences at Case CCC
    • Aaron Gerds named medical director of Clinical Research Office at Case CCC
    • Cantley, Bernstein, Pui receive Medal of Honor award from ACS


  • TCCL Logo

  • Clinical Roundup

    • Immunotherapy combination effective for patients with high-grade neuroendocrine cancer
    • Definitions of malnutrition apply differently depending on cancer type
  • Drugs & Targets

    • FDA approves neratinib for metastatic HER2-positive breast cancer
    • FDA accepts sNDA for Zejula in ovarian cancer indication
    • FDA grants RMAT designation to CD30 CAR-T Cell Therapy in hodgkin lymphoma indication
    • PMC report: FDA addressed rare diseases, expanded cancer treatment and targeted therapies in 2019
    • Boehringer Ingelheim and Trutino Biosciences collaborate to grow cancer immunology portfolio with novel cytokine platform
Issue 8 - Feb 21, 2020